Trends in hormone therapy and breast cancer incidence - Results from the german network of cancer registries

Pathobiology

Volumn 76, Issue 2, 2009, Pages 90-97

  Katalinic, Alexander ^a,b   Lemmer, Anna ^a   Zawinell, Anette ^c   Rawal, Rajesh ^a   Waldmann, Annika ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b Association of Population Based Cancer Registries in Germany   (Germany)

^c AOK Research Institute   (Germany)

Author keywords

Breast cancer incidence; German Network of Cancer Registries; Hormone therapy; Menopause; Risk factors for breast cancer

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; AGED; BREAST CANCER; CANCER REGISTRY; CANCER RISK; CONTROLLED STUDY; FEMALE; HEALTH SURVEY; HORMONAL THERAPY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW;

AGED; BREAST NEOPLASMS; ESTROGENS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GERMANY; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; MIDDLE AGED; PRESCRIPTIONS; REGISTRIES; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 65249143328     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000201677     Document Type: Review

References (27)

1. Rossouw JE, Anderson GL, Prentice RL, La-Croix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321-333.
2. Collaborators MWS:Breast cancer and hormone-replacement therapy in the million women study. Lancet 2003;362:419-427.
3. Flesch-Janys D, Slanger T, Mutschelknauss E, Kropp S, Obi N, Vettorazzi E, Braendle W, Bastert G, Hentschel S, Berger J, Chang-Claude J: Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Ca ncer 2008;123:933-941.
4. Clarke CA, Glaser SL, Uratsu CS, Selby JV, Kushi LH, Herrinton LJ:Recent declines in hormone therapy utilization and breast cancer incidence:clinical and population-based evidence. J Clin Oncol 2006;24:e49-e50.
5. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA: The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007;356:1670-1674.
6. Katalinic A, Rawal R:Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 2008;107:427-430.
7. Heitmann C, Janhsen K, Glaeske G: The influence of published studies and position papers on the prescription of peri- and post-menopausal hormone therapy (in German). Gesundheitswesen 2007;69:379-384.
8. Zahl PH, Maehlen J: A decline in breast-cancer incidence. N Engl J Med 2007;357:510-511;author reply 513.
9. Kerlikowske K, Miglioretti DL, Buist DS, Walker R, Carney PA:Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst 2007; 99:1335-1339.
10. Glass AG, Lacey JV Jr, Carreon JD, Hoover RN:Breast cancer incidence, 1980-2006:combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 2007;99:1152-1161.
11. Bluming AZ: A decline in breast-cancer incidence. N Engl J Med 2007;357:509; author reply 513.
12. Cady B, Chung MA, Michaelson JS:A decline in breast-cancer incidence. N Engl J Med 2007;357:511; author reply 513.
13. Elfenbein GJ: A decline in breast-cancer incidence. N Engl J Med 2007;357:509;aut hor reply 513.
14. Kliewer EV, Demers AA, Nugent ZJ: A decline in breast-cancer incidence. N Engl J Med 2007;357:509-510;author reply 513.
15. Robbins AS, Clarke CA: A decline in breast-cancer incidence. N Eng l J Med 20 07;357: 511-512; author reply 513.
16. Signorello LB, Tarone RE:A decline in breast-cancer incidence. N Engl J Med 2007; 357:512-513; author reply 513.
17. MacMahon B, Cole P: Is the incidence of breast cancer declining? Epidemiology 2008; 19:268-269.
18. Colditz GA:Decline in breast cancer incidence due to removal of promoter:combination estrogen plus progestin. Breast Cancer Res 2007;9:108-110.
19. Stang A:Decline in hormone replacement prescription and fall in breast cancer incidence - an epidemiological discourse. Dtsch Arztebl Int 2008;105:303-309.
20. Cancer in Germany 2003-2004. Incidence and Trends, ed 6. Berlin, Robert Koch Institute and Association of Population-Based Cancer Registries in Germany, 2008.
21. Katalinic A, Stegmaier C, Rawal R, Wald-mann A:Less hormone replacement therapy, less breast cancer in Germany (in German)? Geburtshilfe Frauenheilkd 2007;67:1217-1222.
22. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD index, 2008.
23. Kim HJ, Fay MP, Feuer EJ, Midthune DN: Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000;19:335-351.
24. Keegan TH, Chang ET, John EM, Horn-Ross PL, Wrensch MR, Glaser SL, Clarke CA:Recent changes in breast cancer incidence and risk factor prevalence in San Francisco Bay area and California women:1988 to 2004. Breast Cancer Res 2007;9:R62-R73.
25. Jemal A, Ward E, Thun MJ: Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. Women. Breast Cancer Res 2007;9:R28.
26. Krieger N:Hormone therapy and the rise and perhaps fall of US breast cancer incidence rates:critical reflections. Int J Epidemiol 2008;37:627-637.
27. Berry DA, Ravdin PM:Breast cancer trends: a marriage between clinical trial evidence and epidemiology. J Natl Cancer Inst 2007; 99:1139-1141.